振东制药: 监事会决议公告

Group 1 - The sixth meeting of the supervisory board of Shanxi Zhendong Pharmaceutical Co., Ltd. was held on August 22, 2025, with all three supervisors present, confirming compliance with legal and regulatory requirements [1] - The supervisory board reviewed the 2025 semi-annual report and found that the report accurately reflects the company's actual situation without any false statements or omissions [1] - The semi-annual report and its summary are available on the designated information disclosure website of the China Securities Regulatory Commission [1] Group 2 - The supervisory board approved the proposal for the company and its subsidiaries to use up to RMB 1 billion of idle self-owned funds for cash management, focusing on low to medium-risk financial products [2] - The decision to utilize idle funds is aimed at improving capital efficiency and cash management returns, aligning with the interests of the company and all shareholders, particularly minority shareholders [2] - The cash management proposal complies with relevant regulations and does not involve high-risk investment products as defined by the Shenzhen Stock Exchange [2]